God bless you and guide you towards better choices in the future. Don't hang your head. Use your knowledge to make better choices in the future and make all that money back and than some!
So how big of an opportunity is Z160?
If Z160 reports positive results for both trials, there is no reason to believe a market cap of $600 million isn't achievable in short order. There are myriad examples of biopharmas racing to market caps exceeding $500 million based on strong Phase II results for a potential blockbuster drug. Moreover, such a move would translate into a share price of around $27. Think that's too high? Then check out what happened to Acadia, Keryx, and recently Geron (GERN) after reporting positive clinical data for possible blockbusters. If anything, I believe this estimate is conservative.
I agree. This is very well put. Risky, but not as blind or risky as some other trials out there given the history of the molecule, etc.
I just noticed on StockTwits that one of the writers who covers the company said his article about this news "analysis of this and other upcoming catalysts" is coming on Monday.
I would think this is the big event and that the company already knows exactly what they have!
Bump to keep this on top. Shorts are posting #$%$ nonsense to try to bury this info!
That is a great find!!! I note the following:
The criteria for being selected to present there were:
Large market, large unmet need, with increasing opportunity
History of the molecule and drug
Diversity of indications
Potential for new opportunities beyond the initial indications
Check out the new Seeking Alpha Article. This thing is going to move fast today. Pre-Market activity will be very telling.
Sentiment: Strong Buy
WAY too many shares were bought to and at the $2 level. This one is gonna bounce hard tomorrow.
That may be true, but the article is very balanced and full of FACTS that support what the poster said. The share price is broken here and likely to double as soon as the warrants are all sold out.
Filed in an 8K on Monday after hours. This is an easy DOUBLE from here!
We need to track the garbage written by that writer then invest in those stocks, sounds like.
And your point is?
This made news internationally. I think Garza was spot on!
Great! Now fierce biotech is doing this crap too?!?!
I hope the SEC is looking into this writer and the editor who approved this poorly, poorly researched story!